Interactions between antihyperglycemic drugs and the reninangiotensin system: Putative roles in COVID-19. A mini-review
Fecha
2020Autor
Nakhleh, Afif
Director(es)
Shehadeh, Naim
Documentos PDF
Imagenes y Videos
Resumen
Background: Diabetes mellitus is associated with a more severe course of coronavirus disease 2019
(COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes angiotensinconverting enzyme II (ACE2) receptor for host cell entry. We aimed to assess the interactions between
antihyperglycemic drugs and the renin-angiotensin system (RAS) and their putative roles in COVID-19.
Methods: A literature search was performed using Pubmed to review the interrelationships between
hyperglycemia, RAS and COVID-19, and the effects of antihyperglycemic medications.
Results: The RAS has an essential role in glucose homeostasis and may have a role in COVID-19-induced
lung injury. Some antihyperglycemic medications modulate RAS and might hypothetically alleviate the
deleterious effect of angiotensin II on lung injury. Furthermore, most antihyperglycemic medications
showed anti-inflammatory effects in animal models of lung injury.
Conclusions: Some antihyperglycemic medications might have protective effects against COVID-19-
induced lung injury. Early insulin therapy seems very promising in alleviating lung injury.
Palabras clave
Diabetes mellitus; COVID-19; ACE2; Glucose-lowering medications; Insulin therapyEnlace al recurso
https://doi.org/10.1016/j.dsx.2020.04.040Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.